Journal
CLINICAL NEUROPHARMACOLOGY
Volume 29, Issue 3, Pages 148-153Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.WNF.0000220814.48360.F4
Keywords
Parkinson disease; levetiracetam; dyskinesia
Categories
Ask authors/readers for more resources
Objectives: This open-label study was performed to evaluate the efficacy and tolerability of levetiracetam for levodopa-induced dyskinesia and its effect on motor functioning and quality of life in Parkinson disease (PD) patients. Methods: PD patients with moderate to severe dyskinesia were enrolled in the study. PD medications were unchanged during the study, and levetiracetam was slowly titrated up to a maximum dosage of 3000 mg/d over a 2-month period. Results: There were 9 patients with a mean age of 65 years and mean disease duration of 13 years. Forty-four percent of the subjects withdrew before the end of the study due to adverse events, primarily worsening of PD symptoms and sleepiness. Of the remaining 5 subjects, 1 subject continued levetiracetam after the study with mild improvement in dyskinesia and 4 discontinued levetiracetam due to worsening of PD symptoms and sleepiness. Conclusions: Levetiracetam is not well tolerated in PD patients with levodopa-induced dyskinesia resulting in worsening of PD symptoms, intolerable somnolence, and worsening of dyskinesia in most patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available